Bruker Corporation (NASDAQ:BRKR) Stock Position Lifted by Alberta Investment Management Corp

Key Points

• Alberta Investment Management Corp increased its stake in Bruker Corporation by 98% in the first quarter, totaling 20,193 shares valued at $843,000.
• Bruker reported quarterly earnings of $0.47 per share, beating analyst expectations, and had a revenue of $801.4 million, up 11% year-over-year.
• The company declared a quarterly dividend of $0.05 per share, representing an annualized yield of 0.5%, with a payout ratio of 38.46%.

Alberta Investment Management Corp increased its stake in Bruker Corporation (NASDAQ:BRKR - Free Report) by 98.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,193 shares of the medical research company's stock after purchasing an additional 9,994 shares during the quarter. Alberta Investment Management Corp's holdings in Bruker were worth $843,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. London Co. of Virginia raised its position in shares of Bruker by 78.4% in the 4th quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock worth $245,820,000 after acquiring an additional 1,843,294 shares in the last quarter. Sculptor Capital LP grew its position in shares of Bruker by 484.1% during the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after purchasing an additional 1,420,569 shares in the last quarter. FIL Ltd grew its position in Bruker by 262.3% in the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock worth $114,978,000 after acquiring an additional 1,420,102 shares in the last quarter. Steadfast Capital Management LP purchased a new stake in shares of Bruker in the fourth quarter valued at approximately $63,997,000. Finally, Marshall Wace LLP raised its stake in Bruker by 4,510.3% in the fourth quarter. Marshall Wace LLP now owns 783,988 shares of the medical research company's stock worth $45,957,000 after buying an additional 766,983 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Frank H. Laukien acquired 2,608 shares of the stock in a transaction that occurred on Friday, June 6th. The shares were purchased at an average cost of $38.36 per share, with a total value of $100,042.88. Following the completion of the transaction, the chief executive officer owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This trade represents a 0.01% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 27.30% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on BRKR shares. Bank of America lowered their price target on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Citigroup lowered their target price on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday. Jefferies Financial Group cut their price target on shares of Bruker from $70.00 to $60.00 and set a "buy" rating for the company in a report on Monday. The Goldman Sachs Group lowered their price target on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Finally, UBS Group decreased their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $51.30.

Bruker Stock Performance

Bruker stock traded down $2.65 during midday trading on Tuesday, reaching $32.07. 5,895,045 shares of the stock traded hands, compared to its average volume of 3,703,590. The company has a current ratio of 1.61, a quick ratio of 0.74 and a debt-to-equity ratio of 1.31. The firm has a fifty day moving average price of $39.93 and a two-hundred day moving average price of $43.20. The firm has a market cap of $4.86 billion, a price-to-earnings ratio of 61.67, a PEG ratio of 2.34 and a beta of 1.16. Bruker Corporation has a fifty-two week low of $32.01 and a fifty-two week high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%. The company had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. During the same quarter last year, the firm posted $0.52 earnings per share. The firm's quarterly revenue was down .4% compared to the same quarter last year. On average, equities research analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. Bruker's payout ratio is presently 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.